Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjusted Doses of Darunavir/Ritonavir With Rifampicin in HIV
NCT03892161Phase 1Terminated
- Sponsor
- University of Cape Town
- Start
- Apr 2018
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of darunavir in human immunodeficiency virus infection (HIV) (5 arms), sponsored by University of Cape Town. Primary endpoint: Darunavir plasma concentrations at 1 year. Started Apr 2018; status: terminated.
02
Drugs
darunavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03892161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03892161.